• WHO set to endorse weight-loss drugs for adults with obesity, marking a pivotal shift in global treatment guidelines.
  • GLP-1 agonists like Wegovy and Zepbound could become first obesity medications on WHO's Essential Medicines List.
  • Decision expected to accelerate market growth and expand access, though cost and supply challenges remain.

A Watershed Moment for Obesity Treatment

The World Health Organization is preparing to recommend pharmaceutical interventions for obesity management, according to internal documents reviewed by Reuters. This represents a fundamental change in approach for the global health body, which currently doesn't list any obesity medications on its Essential Medicines List.

The recommendations, expected to be finalized by April 2025, focus primarily on GLP-1 receptor agonists like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide). These drugs have demonstrated unprecedented efficacy in clinical trials, with some patients achieving 15-20% body weight reduction.

"This would fundamentally change how we approach obesity globally," said one pharmaceutical executive familiar with the discussions, speaking on condition of anonymity. "It moves obesity from being seen primarily as a lifestyle issue to a treatable medical condition."

Market and Access Implications

The potential WHO endorsement comes as the global obesity medication market surpasses $30 billion in annual spending. Analysts suggest inclusion on the Essential Medicines List could dramatically expand access in developing markets, though significant hurdles remain around pricing and manufacturing capacity.

Novo Nordisk and Eli Lilly have both faced supply constraints for their blockbuster drugs, with demand far outstripping production capabilities. Industry sources indicate both companies are rapidly scaling manufacturing, with new facilities coming online throughout 2025.

The WHO's decision follows updated FDA guidance on obesity drug development and comes as clinical evidence mounts for the long-term benefits of these medications beyond weight loss alone, including cardiovascular risk reduction.

Looking Ahead

While the WHO's move would provide important validation, questions persist about sustainable pricing models and the drugs' long-term safety profile. Some health economists warn that broad adoption could strain healthcare budgets in lower-income countries unless significant price reductions are achieved.

The final recommendations, expected next year, will likely include guidance on appropriate patient populations and treatment duration. Pharmaceutical companies are already preparing for expanded global demand, with several next-generation obesity treatments in late-stage clinical trials.